Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | FLT4 | P35916 | 4/20 | 0.67 |
| ▸ | APP | P05067 | 3/20 | 0.66 |
| ▸ | GLA | P06280 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 5/20 | 0.60 |
| ▸ | INSR | P06213 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MMP9 | P14780 | 2/20 | 0.58 |
| ▸ | MMP8 | P22894 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25547107 | 0.95 | NPC1 (0.77) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL24155562 | 0.92 | APP (0.76) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL14195557 | 0.89 | APP (0.71) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL22879575 | 0.88 | APP (0.69) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL5260406 | 0.86 | RAB9A (0.61) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL4729573 | 0.85 | RAB9A (1.00) | NPC1RAB9AKDM4EAPPGLA | |
| SCHEMBL24156180 | 0.83 | NPC1 (0.71) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL4593253 | 0.83 | FLT4 (0.71) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL26467173 | 0.82 | FLT4 (0.64) | NPC1RAB9AKDM4EFLT4APP | |
| SCHEMBL8397393 | 0.82 | APP (0.76) | NPC1RAB9AKDM4EFLT4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910349-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009524-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009524-A1 | 2-ARYLBENZOTHIAZOLES AND USES THEREOF | 4SC AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | 4SC AG (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746096-A1 | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer | 4SC AG (DE) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021446-A1 | 2-arylbenzothiazole analogues and uses thereof | NR2E1, NR2E3, NR0B2 | NPC1 4075/4885RAB9A 3722/4885KDM4E 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.